Correspondence 0001213900-22-079843 from Scinai Immunotherapeutics Ltd. (SCNI)
Scinai Immunotherapeutics Ltd.
Date: Dec. 14, 2022 · CIK: 0001611747 · Accession: 0001213900-22-079843
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-267648
Letter
BiondVax Pharmaceuticals Ltd.
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
December 14, 2022
Via EDGAR Transmission
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
BiondVax Pharmaceuticals Ltd.
Registration Statement on Form F-1
Filed September 29, 2022, as amended
Registration No. 333-267648
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on December 15, 2022 at 4:15 p.m. Eastern Time or as soon thereafter as practicable, or at such later time as BiondVax Pharmaceuticals Ltd. (the “Company”) or its counsel may request via telephone call to the staff.
Please contact Steven A. Lipstein of Lucosky Brookman LLP, counsel to the Company, at (732) 395-4416, or in his absence, Perry Wildes of Gross & Co., counsel to the Company, at + 972-545651-137, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Sincerely yours,
BiondVax Pharmaceuticals Ltd.
Show Raw Text
CORRESP
1
filename1.htm
BiondVax Pharmaceuticals Ltd.
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
December 14, 2022
Via EDGAR Transmission
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
BiondVax Pharmaceuticals Ltd.
Registration Statement on Form F-1
Filed September 29, 2022, as amended
Registration No. 333-267648
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of
the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date
of the above-referenced Registration Statement so that it will become effective on December 15, 2022 at 4:15 p.m. Eastern Time or as soon
thereafter as practicable, or at such later time as BiondVax Pharmaceuticals Ltd. (the “Company”) or its counsel may
request via telephone call to the staff.
Please contact Steven A. Lipstein of Lucosky Brookman
LLP, counsel to the Company, at (732) 395-4416, or in his absence, Perry Wildes of Gross & Co., counsel to the Company, at + 972-545651-137,
to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Sincerely yours,
BiondVax Pharmaceuticals Ltd.
By:
/s/ Amir Reichman
Amir Reichman
Chief Executive Officer
cc:
Steven A. Lipstein, Lucosky Brookman LLP
Perry Wildes, Gross & Co.